To the Editor On behalf of my coauthors, I write to report an omission of data from 1 trial reported in our article, “Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis,” that was published online first on March 13, 2017, and in the June 2017 issue of JAMA Internal Medicine.¹ We are grateful to the reader who pointed out this omission and for the opportunity to correct the article. Our meta-analysis included data from 9 trials comprising 8127 patients that compared major renal outcomes in nondiabetic patients with chronic kidney disease (CKD) who received intensive blood pressure (BP) control (<130/80 mm Hg) vs standard BP control (<140/90 mm Hg). We inadvertently failed to include mortality data from the SPRINT trial² in the summary estimate for overall mortality.

致编辑我谨代表我的合著者，报道我们一项文章“在非糖尿病慢性肾脏病患者中进行强化血压控制与肾脏疾病进展的关联：系统评价和荟萃分析”中一项试验的数据遗漏。分析”，该报告于2017年3月13日首次在线发表，并于2017年6月发行的《JAMA Internal Medicine》中发表。^1个我们感谢指出这一遗漏的读者，并感谢有机会更正本文。我们的荟萃分析包括来自9项试验的数据，这些试验包括8127名患者，这些患者比较了接受强血压（BP）对照（<130/80 mm Hg）与标准BP对照（< 140/90毫米汞柱）。我们无意间未能将SPRINT试验^2的死亡率数据纳入总体死亡率的概算中。